RetaMaps

Trouvaille Med Spa

Trouvaille Med Spa · 9501 West 171st Street · Tinley Park, IL 60487

4.7· 703 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

Care described on the practice's website

  • Medically supervised weight loss

About this practice

Trouvaille Med Spa is a medical spa in Tinley Park, Illinois, whose listing includes weight-loss care alongside aesthetics. Its website describes personalized, approachable aesthetic care, with injectables, fillers, laser hair removal, complexion lasers and customized skincare, and says it serves patients throughout the Chicago area. On Google it holds a 4.7-star rating across 703 reviews dating back to 2020, with 42 in the past year; reviewers most often mention the providers' knowledge and the staff, and 7 mention scheduling.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsNot listed
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 4.7
Google rating · 703 reviews
42
reviews in the past year (avg ★ 4.9)
1
reviews mention weight loss

Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-17. Read the reviews themselves on the practice's Google listing.

What patients say

Rated ★4.7 across 703 Google reviews. Of the 100 reviews we analyzed, 96 (96%) are positive (4–5★) and 3 (3%) are negative (1–2★).

What patients like

  • Friendly, helpful staff20 reviews
  • Knowledgeable, professional providers20 reviews
  • Weight-loss results10 reviews
  • Easy scheduling and communication6 reviews

Common complaints

  • Disappointing results3 of 3 negative
5★
95
4★
1
3★
1
2★
1
1★
2

Most recent Google reviews

Denise O.★★★★★2026-09-17

I had a great experience here! The place is beautifully decorated. And I had beautiful Tara for my treatment. She was so informative about what she was doing & very sweet!

Ghada A.★★★★★2026-09-15

⭐️ Extremely disappointed with my Botox experience. I received 41 units of Botox here, and after only about one month, the results were essentially gone. My facial movement and lines returned almost completely. For the amount I paid, I expected a much longer-lasting result. I gave it time and waited to see how the Botox would develop, but unfortunately the results simply did not last. I have never been this disappointed with a Botox treatment. This is based solely on my personal experience, but unfortunately I would not return here for Botox.

joe s.★★★★★2026-07-30

I owe 35 miles each way to take my dog. Debbie and Jim are the best.

c g.★★★★★2026-06-28

Staff was friendly and professional.

DevM★★★★★2026-06-24

Highly recommend - Staff is SO knowledgeable and friendly!!

Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.

Nearby providers in Tinley Park

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs